Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2026 02:00 ET | Source: Reset Health

Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota

LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the Company”), the experts in the personalised management of chronic disease, today announces Pinder Sahota has joined the Company as a...
February 10, 2026 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide

Kailera and Hengrui report positive topline data from Hengrui’s Phase 2 clinical trial of oral ribupatide, a GLP-1/GIP receptor dual agonist peptide.
February 09, 2026 06:59 ET | Source: Novo Nordisk A/S

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.
February 04, 2026 08:00 ET | Source: Noom Inc

The Noom Engagement Report: New Data Shows that the GLP-1 Patients Who Use Noom the Most Also Lose the Most Weight and Stay On Medication Program Longest

Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app.
January 30, 2026 06:28 ET | Source: BCC Research LLC

Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030

Global GLP-1 Analogues Market report, the market was valued at $54.8 billion in 2024 and is projected to reach $268.4 billion by 2030.
January 15, 2026 03:26 ET | Source: Digbi Health

Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs

MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Digbi Health, the national leader in Precision Biology–based chronic care, today announced peer-reviewed, actuarially validated significant...
January 12, 2026 18:45 ET | Source: RO

Wegovy Pill Legitimacy Examined: 2026 Consumer Analysis Investigates Ro's Oral GLP-1 Access Pathway and No-Insurance Cash-Pay Options

Wegovy Pill by Ro: January 2026 consumer analysis examines oral GLP-1 legitimacy, Novo Nordisk integration, and no-insurance cash-pay options.
January 12, 2026 08:30 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Kailera announced the first participants randomized in the global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide (KAI-9531).
January 10, 2026 17:53 ET | Source: ColonBroom

ColonBroom GLP-1 Booster Ingredients Investigated: 2026 Consumer Analysis Examines Colon Broom GLP-1 Formulation Disclosures

ColonBroom GLP-1 Booster ingredient disclosure and formula transparency examined as January 2026 consumer metabolic supplement research continues
January 08, 2026 09:00 ET | Source: Omada Health, Inc.

Omada Health’s GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss

Omada Health’s new analysis adds to existing evidence that its GLP-1 companion program helps drive lasting, long-term weight loss